Skip to main content
. 2023 Dec 14;15(12):e50507. doi: 10.7759/cureus.50507

Figure 1. Comparison of remission/low disease activity achieved.

Figure 1

csDMARDs: conventional synthetic disease-modifying anti-rheumatic drugs; bDMARDs: biologic disease-modifying anti-rheumatic drugs